secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seer, Inc. (SEER)
CIK:        0001726445
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000950170-24-122309
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seer Q3 2024 revenue $4.0M, net loss $21.3M; FY guidance reaffirmed $13-15M
---------------------------------------------------------------------------

- Q3 revenue $4.0M vs $4.2M YoY (down 3%); product revenue $3.1M, service $847K, grant $90K.
- Net loss $21.3M vs $21.1M YoY; gross margin 48%; operating expenses down 6% to $26.3M.
- Repurchased 3.7M shares at avg $1.78 in Q3; total 5.7M shares repurchased to date.
- Entered co-marketing agreement with Thermo Fisher Scientific for Proteograph suite with Orbitrap Astral mass specs.
- Cash, equivalents & investments $312M; FY 2024 revenue guidance reaffirmed at $13-15M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726445/000095017024122309/0000950170-24-122309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726445/000095017024122309/ck0001726445-20241106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer